FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office - KFF Health News
Source: KHN
While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the cheaper medicines to get on the market, industry officials say. These officials were thrilled Oct. 29 when FDA Commissioner Marty Makary announced the agency’s plan, which he said would halve the time and money needed…
This is aggregated or syndicated coverage. Reporting and media belong to the original publisher.
Read the original source at KHN